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a b s t r a c t
Nanog, a core pluripotency factor, is required for stabilizing pluripotency of inner cell mass (ICM) and
embryonic stem cells (ESCs), and survival of primordial germ cells in mice. Here, we have addressed function
and regulation of Nanog in epiblasts of postimplantation mouse embryos by conditional knockdown (KD),
chromatin immunoprecipitation (ChIP) using in vivo epiblasts, and protein interaction with the Nanog
promoter in vitro. Differentiation of Nanog-KD epiblasts demonstrated requirement for Nanog in stabilization
of pluripotency. Nanog expression in epiblast is directly regulated by Nodal/Smad2 pathway in a visceral
endoderm-dependent manner. Notably, Nanog promoters switch from Oct4/Esrrb in ICM/ESCs to Oct4/
Smad2 in epiblasts. Smad2 directly associates with Oct4 to form Nanog promoting protein complex.
Collectively, these data demonstrate that Nanog plays a key role in stabilizing Epiblast pluripotency mediated
by Nodal/Smad2 signaling, which is involved in Nanog promoter switching in early developing embryos.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Nanog, a homeodomain-bearing transcription factor, plays a
crucial role in early mouse embryonic development. Nanog
expression has been detected in cells of the inner cell mass
(ICM) of E3.5 blastocyst, the epiblast of E5.5–E7.5 embryos in the
egg-cylinder into the primitive streak stages, and primordial germ
cells (PGCs) of E8.5–E13.5 embryos in the headfold into the 52–55
somite stages (Chambers et al., 2003; Hatano et al., 2005; Mitsui et
al., 2003; Yamaguchi et al., 2005). In pluripotent ICM cells and
ICM-derived mouse embryonic stem cells (ESCs), Nanog has been
identiﬁed as a central component of the regulatory circuitry in
conjunction with Oct4 and Sox2. Disruption of Nanog halted
development of ICM into epiblast at the peri-implantation stage
(Mitsui et al., 2003), indicating requirement for Nanog in normal
embryonic development. In ESCs, constitutive expression of Nanog
entails cytokine-independent self-renewal in ESCs, and reduces
the propensity to differentiate (Chambers et al., 2003), while
cytokines such as leukemia inhibitory factor (LIF) and bone
morphogenic factor-4 (BMP4) are required to maintain ESC
identity in vitro (Qi et al., 2004; Smith et al., 1988; Williams
et al., 1988). Further analysis has revealed that loss of Nanog
severely compromises the robust pluripotency feedback networks,
and leads to a concomitant cell fate decision to differentiate
following deterioration of the self-perpetuating pluripotent state
(MacArthur et al., 2012). In PGCs, Nanog is required for proper
germ cell development. Nanog-knockout ESCs fail to contribute to
germ cells of chimeric embryos (Chambers et al., 2007), and
inducible Nanog-knockdown triggers apoptotic cell death of PGCs
via disruption of a PGC-speciﬁc molecular network (Yamaguchi et
al., 2009). Together, the data demonstrate that Nanog plays a
crucial role in normal embryonic development through differential
functioning between ICM cells and PGCs. However, it has not yet
been investigated whether Nanog is required and how Nanog
expression is regulated in the epiblast of E5.5–E7.5 embryos,
between the egg-cylinder and primitive streak stages.
Mouse epiblast stem cells (EpiSCs), which are pluripotent cells
derived from the epiblast, resemble human ESCs, but not mouse
ESCs, in colony morphology and expression of pluripotency marker
genes (Brons et al., 2007; Tesar et al., 2007). EpiSCs readily form
teratoma, but not chimeric embryos following injection into blas-
tocysts. Notably, core pluripotency regulators, Oct4, Sox2, and Nanog
are expressed in both EpiSCs and ESCs, while expression of Klf4,
Stella, and Esrrb are attenuated in EpiSCs, but not in ESCs. Further-
more, EpiSCs require bFGF and TGFb/ActivinA signaling, while ESCs
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respond to LIF/Stat3 and BMP4 signals, to support self-renewal under
culture conditions. Collectively, EpiSCs are pluripotent stem cells
maintained under a primed state, distinctive from ESCs under a naïve
state (Nichols and Smith, 2009). As a model of the epiblast, EpiSCs
have been used for investigating regulatory mechanisms of Nanog
(Greber et al., 2010; Vallier et al., 2009). Nanog functions as a
safeguard of pluripotency by blocking neuroectoderm and endoderm
differentiation in vitro (Vallier et al., 2009). In EpiSCs, Nanog expres-
sion relies predominantly on ActivinA signaling through direct
association of Smad2, but not Smad3, with the Nanog promoter
region (Sakaki-Yumoto et al., 2013; Vallier et al., 2009). In contrast, in
ESCs, Oct4, Sox2, and Esrrb, which are key factors of a master
complex that also binds to the promoter region of Nanog, are
responsible for upregulating Nanog expression (Kuroda et al., 2005;
Rodda et al., 2005; van den Berg et al., 2008). Therefore, transcription
regulation of Nanog in EpiSCs is different from that in ESCs, suggest-
ing that switching of transcriptional regulation may occur during
embryonic development from the ICM to the epiblast. However the
underlying mechanism is unknown.
Importantly, in the epiblast of postimplantation embryos, axial
patterning occurs through extracellular signals provided by extraem-
bryonic tissues (Beddington and Robertson, 1999; Tam and Loebel,
2007). One of the most important signaling molecules is Nodal
(Brennan et al., 2001). In embryos at the egg-cylinder stage, embryonic
visceral endoderm (VE) surrounds and supports growing pluripotent
epiblast through Nodal signaling (Mesnard et al., 2006). Nodal
processing by proprotein convertases Spc1 and Spc4 released from
extraembryonic ectoderm (EXE) is essential for Nodal maturation and
signaling in epiblast (Beck et al., 2002; Ben-Haim et al., 2006). The
distal end of VE, which emerges in response to coordinated Nodal and
BMP4 signaling in the E5.5 embryo (Brennan et al., 2001; Soares et al.,
2005), migrates to the anterior region of the egg-cylinder embryo to
form anterior VE (Kimura-Yoshida et al., 2005; Yamamoto et al., 2004).
Anterior VE expresses Nodal antagonists Cer1 and Lefty1 that attenu-
ate the effect of Nodal signaling and established the anterior–posterior
patterning of the epiblast (Yamamoto et al., 2004). This anterior–
posterior polarity is required for formation of the primitive streak.
Ablation of Nodal expression promotes neural fate determination in
the epiblast (Camus et al., 2006), suggesting that Nodal is associated
with both maintenance of pluripotency and lineage speciﬁcation.
Here, we have investigated the function of Nanog in post-
implantation epiblast ex vivo using a conditional knockdown system.
Nanog was required for maintenance of pluripotency in epiblast
explants. In E6.5 embryos, the Nanog expression pattern overlapped
with the Nodal expression pattern. Nanog expression in epiblasts was
induced by Nodal in a VE-dependent manner. Notably, Smad2, a
downstream effector of Nodal signaling, upregulated Nanog expression
in association with Oct4 through binding to the Nanog promoter
region that includes the Oct/Sox- and Smad2/Esrrb-binding elements.
Switching of transcription regulation of Nanog occurred ﬁrst in
development of the epiblast in the early egg-cylinder embryos with
silencing of Esrrb, followed by formation of anterior–posterior axis
patterning in the epiblast of late egg-cylinder embryos with down-
regulation of Sox2 in the posterior region. Smad2 and Oct4 were core
regulators of Nanog in the epiblast.
Results
Nanog is required for maintaining pluripotency in E6.5 epiblast
To explore function of Nanog in the epiblast, a 4-hydroxytamoxifen
(TM)-inducible knockdown (KD) system (Yamaguchi et al., 2009) was
applied to early postimplantation in vivo embryos, which were
heterozygous for the Nanog shRNA transgene (NRi-Tg) and ER-Cre
generated by mating of NRi-Tg (þ/þ) females with ER-Cre (þ/)
males (Fig. 1A). Unfortunately, effects of Nanog knockdownwas unable
to be analyzed in vivo egg-cylinder stage embryos, because E6.5
double and single transgenic embryos died due to detrimental effect
of TM peritoneal-injection into 5.0–5.5-day pregnant females. Nanog
was downregulated within 24 h of TM induction as previously
demonstrated (Yamaguchi et al., 2009). Hence, we examined functions
of Nanog using ex vivo culture of E6.5 epiblasts isolated from
surrounding extraembryonic (EXE) tissue and VE (Fig. 1A). Genotype
of embryos was determined by PCR with EXE tissues. Epiblast was
dissected into ﬁve pieces and plated onto MEF feeders with TM for
4 days (Fig. 1B). At day 1 after plating, all epiblast clumps formed ﬂat-
shaped colony morphology, which resembles primed-state pluripotent
stem cell colony, and we call it EpiSC-like colonies here. Notably,
colonies of the double transgenic ER-Cre/NRi-Tg (Nanog KD), but not
single transgenic NRi-Tg (negative control), epiblast started dissociat-
ing into single cells at day 4 (Fig. 1B and C), indicating that TM-induced
Nanog KD exerted deleterious effect on maintenance of EpiSC-like
colonies. The Nanog KD-mediated effect was prominent at day 10 (Fig.
S1A), where the survival rate of EpiSC-like colonies was dramatically
reduced to less than 5% at day 10 from about 30% at day 4 in ER-Cre/
NRi-Tg epiblasts (Fig. 1C). In contrast, more than 50% EpiSC-like
colonies survived between day 4 and 10 in NRi-Tg epiblasts. These
data demonstrated that Nanog was required for maintenance of stem
cell properties in the epiblast of early postimplanation embryos.
Next, to investigate whether the Nanog KD-mediated disrup-
tion of EpiSC-like colony formation was caused by induction of cell
differentiation, expression of pluripotency marker, Oct4, the meso-
derm marker, Flk1, and the endoderm/trophectoderm marker,
Cdx2, in three individual Nanog KD and negative control epiblast
explants at day 10 were analyzed by qPCR. In Nanog KD epiblasts
(ER-Cre/NRi-Tg), Oct4 expression decreased, and lineage-speciﬁc
markers, Flk1 and Cdx2 increased, compared to negative control
epiblasts (NRi-Tg) (Fig. 1D). Furthermore, to address whether cell
death played a role in loss of stem cell-like colonies, the pan-
caspase inhibitor, Z-VAD-FMK, was supplemented in the media for
in vitro epiblast culture. However, loss of colony forming ability
was not rescued by the inhibition of apoptosis (Fig. S1B). Taken
together, the data indicate that Nanog serves as a crucial factor in
maintaining pluripotency in the epiblast of post-implantation
embryos.
Nanog co-localizes with Oct4 but not Sox2 in E6.5 epiblast
Skewed expression of Nanog to the posterior region of the
epiblast of E6.5 and E7.5 embryos has been previously demon-
strated by immunostaining and mRNA in situ hybridization, in
contrast with even expression in the epiblast of E5.5 embryos
(Hart et al., 2004; Hatano et al., 2005; Osorno et al., 2012).
To conﬁrm skewed expression of Nanog in the E6.5 embryo, we
visualized the reporter gene, GFP, in Nanog-GFP transgenic mice
(Okita et al., 2007). Nanog expression was detected in the posterior
region of the E6.5 epiblast, but not in the anterior region (Fig. 2A).
Next, to compare the expression proﬁle of other pluripotency core
factors, Oct4 and Sox2, with that of Nanog, quantitative RT-PCR
was carried out in the anterior and posterior regions of the E6.5
epiblast. Successful separation of the anterior and posterior
regions was veriﬁed by high expression of the mesoderm-
speciﬁc gene, Brachyury, in the posterior region (Rivera-Perez
and Magnuson, 2005). Notably, in the posterior regions, Nanog
and Oct4 were highly expressed, while Sox2 expression was
extremely low (Fig. 2B), and the skewed expression of Nanog
and Sox2 was conﬁrmed by immunoﬂuorescent staining of plur-
ipotency markers on intact embryos in gastrulation (Hoffman et al.,
2013). Inconsistent with this observation, both Oct4 and Sox2 have
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been previously identiﬁed as core regulators of Nanog through
binding to the Oct4/Sox2 motif upstream of the transcription-starting
site of Nanog in ESCs (Kuroda et al., 2005; Rodda et al., 2005).
We speculated that Nanog, which plays an important role in
maintenance of pluripotency at the epiblast stage, was regulated
by a mechanism distinct from ESCs.
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Fig. 1. Requirement of Nanog in E6.5 epiblast shown by conditional Nanog knockdown: (A) a Lentiviral vector for Cre-inducible Nanog RNA interference with shRNA (Left)
and experimental scheme to collect epiblasts from E6.5 embryos for in vitro culture (Right). For obtaining E6.5 embryos, females homozygous for NRi-Tg were mated with
males heterozygous for ER-Cre. GFP (green); green ﬂuorescence protein, U6 (yellow) and CMV (blue); promoter sequences, shRNA (pink); short hairpin RNA inducing RNAi of
Nanog, LoxP (white); LoxP sequences, between where Cre recombinase catalyzes DNA recombination event, TM; 4-hydroxytamoxifen, up-regulates Cre recombinase through
binding to the ER promoter of the ER-Cre transgene, ER: estrogen receptor, VE; visceral endoderm, EXE; extraembryonic ectoderm. (B) Sequential changes of epiblast cell
colonies ex-vivo cultured with Nanog knockdown inducer, tamoxifen (TM). Cell differentiation is observed in the double transgenic, ER-Cre/NRi-Tg, epiblast 4 days after TM
treatment, while stem cell-like cells are propagated in the single transgenic, NRi-Tg, epiblast. (C) Generation efﬁciency of EpiSC-like colonies 4 and 10 days after TM
treatment in culture. Nanog knockdown was induced in ER-Cre/NRi-Tg double transgenic (pink column), but not NRi-Tg single transgenic (gray column) epiblasts. The
number of stem cell colonies at day 1 (indicated as n) was used as the reference to calculate the percentage of EpiSC-like colonies remaining after 4 and 10 days of TM
treatment. (D) Comparative expression analysis of pluripotency and differentiation marker genes in epiblasts with or without Nanog knockdown (KD) by quantitative PCR.
Nanog KD was induced in ER-Cre/NRi-Tg double transgenic epiblasts, while not in NRi-Tg single transgenic epiblasts. One of the NRi-Tg embryos was used as the reference.
Oct4; pluripotency marker, Flk1; mesoderm marker, Cdx2; endoderm and trophectoderm marker.
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Nanog expression is regulated by Nodal signaling in a visceral
endoderm-dependent manner
To explore transcriptional regulation of Nanog in E5.5 Nanog-
GFP embryos, epiblast was either carefully removed from the
encapsulating VE or kept with VE intact (Fig. 3A). GFP expression
was detected in 7 out of 8 intact epiblasts, while only 1 out of 7
VE-free epiblast was GFP positive (Fig. 3B). Expression of Nodal, a
protein related to transforming growth factor-beta (TGF-beta),
patterns VE and activates phosphorylation of Smad2, which
recruits transcriptional factors to promote gene expression in
developing embryos (Brennan et al., 2001; Kumar et al., 2001;
Schier, 2003). Recombinant Nodal has previously been shown to
rescue Cripto expression in VE-free epiblasts (Beck et al., 2002).
Hence, epiblasts without VE were treated with or without Nodal.
Remarkably, and GFP expression was detected with (7 out of 8) but
not without (1 out of 7) Nodal in VE-free epiblasts. Consistent with
our ﬁndings, the Nodal expression pattern agreed with that of
Nanog in E6.5 mouse embryos (Conlon et al., 1994). Our results
with the previous reports (Brennan et al., 2001; Kumar et al., 2001;
Schier, 2003) indicated that expression of Nanog in the epiblast
is regulated through Nodal/Smad2 signaling pathway in a
VE-dependent manner (Fig. 3C).
For further analysis of Nanog expression in the epiblast of early
implantation embryos, one of the core regulators of Nanog, Sox2,
which plays crucial role in regulating Nanog transcription through
binding to the Oct4/Sox2 element in ESCs, was examined by
immunohistochemistry. Interestingly, Nanog was repressed in
E5.5 VE-free epiblasts, in which Sox2 was expressed (Fig. 3C),
suggesting that Oct4 and Sox2 alone may not maintain Nanog
expression and transcriptional regulation of Nanog has been
switched either partially or fully from Oct4/Sox2 motif-
dependent to Nodal/Smad2-dependent mechanism around E5.5.
Binding of Oct4 and Smad2 to Nanog promoter in E6.5 epiblast
To examine which transcription factors are binding to the
promoter region of Nanog in the E6.5 epiblast, chromatin immu-
noprecipitation (ChIP) assays were performed. Recently, it has
been shown that Esrrb plays an important role in maintaining
pluripotency and regulating Nanog expression through binding to
a region located upstream of the Oct4/Sox2 element in the Nanog
proximal promoter region in ESCs (van den Berg et al., 2008). The
Esrrb binding site overlaps with Smad2 binding site previously
reported in EpiSCs (Fig. 4B) (Greber et al., 2010; Vallier et al.,
2009). Therefore, Esrrb was included in ChIP assays to reveal the
relationship among Nanog regulators in developing embryos. ESCs
and EpiSCs were used as references in ChIP. In all ChIP experi-
ments, there were no signiﬁcant difference between the control
regions A and C (Fig. 4C).
In ESCs, Nanog, Oct4, Sox2, Esrrb, and Smad2 were expressed
(Fig. 4A), and Oct4 and Esrrb predominantly bound to the Nanog
promoter (Fig. 4B and C), as previously reported (van den Berg et
al., 2008). In EpiSCs, Nanog, Oct4, Sox2, and Smad2, but not Esrrb
were expressed (Fig. 4A), and Oct4 and Smad2 bound to the Nanog
promoter (Fig. 4B and C). Notably, in the E6.5 epiblast, Nanog, Oct4,
and Smad2, but not Sox2 and Esrrb were expressed in the posterior
region, and Oct4 and Smad2 bound to the Nanog promoter (Fig. 4B
and C). The expression proﬁle of pluripotency genes in ESCs and
EpiSCs corresponded to that of inner cell mass cells (ICM) of the
blastocyst and the E5.5 epiblast, respectively (Fig. 4A), with respect
to Nanog transcriptional regulation. Therefore, our data demon-
strated that occupancy of the Nanog promoter switched from
Esrrb/Oct4 in the ESC/ICM to Smad2/Oct4 in the EpiSC/E5.5
epiblast. Smad2/Oct4 continued to occupy the Nanog promoter
in the posterior region of E6.5 epiblast for driving Nanog expres-
sion despite down-regulation of Sox2. Due to technical difﬁculties,
we could not obtain quality Sox2 ChIP results with limited epiblast
samples, and hence whether Sox2 participates in regulating Nanog
expression in E6.5 epiblast remains unclear. However, our obser-
vations in Sox2 patterning (Fig. 2B) and immunostaining of E5.5
epiblast (Fig. 3C) indicated that Sox2 is dispensable for Nanog
expression in developing epiblast.
ChIP analysis of Esrrb was not performed since Esrrb was
repressed in the EpiSC (Fig. 2A) and the epiblast (Osorno et al., 2012).
Smad2/Esrrb and Oct4 binding sites are required for Nanog
expression
Due to the limited options for assays that could be applied to
early embryonic tissues, we assessed the possibility of using
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EpiSCs as a reliable model for investigating Epiblast biology. With
multiple lines of evidence shared between epiblast and EpiSCs,
including downregulation of Esrrb, Nodal/ActivinA/Smad2 depen-
dency of Nanog expression, and occupancy of both Smad2 and
Oct4 on the Nanog promoter (Fig. 4C), we concluded that EpiSCs
was a suitable model for speciﬁcally analyzing the Nanog promoter
landscape in the epiblast.
To examine whether the Oct4/Sox2 and Smad2/Esrrb binding
sites are required in promoting Nanog expression, triple point
mutations were introduced by replacement of DNA residues in
each of Oct4, Sox2, Smad2, and Esrrb binding site (Fig. 5A) into
previously cloned Nanog promoter-activated luciferase constructs
(Kuroda et al., 2005). Wild type and mutated constructs were
transfected into ESCs, EpiSCs, and NIH3T3 ﬁbroblasts, which do
not express Nanog. In ESCs and EpiSCs, all constructs with the Oct4
mutation showed a dramatic reduction in luciferase activity
(Figs. 5B and S1D), indicating that Oct4 binding to the Nanog
promoter is essential for upregulation of Nanog. Mutation of Sox
element or Esrrb binding site with retention of the wild type Oct4
binding site induced considerable reduction of luciferase activity
in both ESCs and EpiSCs (Fig. 5B). Conversely, mutations of the
Smad2 binding site alone reduced luciferase activity only slightly
in ESCs, but the effect of this mutation was signiﬁcant in EpiSCs.
Since Esrrb binding site overlapped with a signiﬁcant portion of
Smad2 binding site, a slight reduction in luciferase activity in ESCs
transfected with Smad2-mutated construct was expected. Yet, it
was remarkable that mutation in Smad2 and Esrrb binding sites
demonstrate a similar level of luciferase activity in EpiSCs. This
observation indicated that Esrrb was not a dominant promoter of
Nanog in EpiSCs, and Esrrb and Smad2 binding sites might
respond to a common promoter, while they were functionally
separable and distinctively different in ESCs, suggesting a
promoter-changing event might occur between ESCs and EpiSCs.
Since Esrrb expression was nearly silenced in EpiSCs (Fig. 4A),
Smad2 might substitute for Esrrb to bind the Nanog promoter.
It was evident that binding of Oct4 to the Oct4/Sox2 motif was
crucial for Nanog upregulation (Fig. 5B). To address whether the
Oct4 transcription complex contained Smad2 as a cofactor,
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immunoprecipitation assays were performed with anti-Oct4, anti-
Nanog, and anti-Smad2 antibodies. In ESCs, Smad2 was free from
the Oct4/Nanog complex (Fig. 5C), consistent with the observation
that Esrrb occupied the Smad2/Esrrb binding site, and made a
complex with Oct4 (van den Berg et al., 2008). In EpiSCs, Smad2
bound Oct4, but not Nanog (Fig. 5C), suggesting that Smad2 could
induce Nanog upregulation as a co-factor of the Oct4 complex
through direct binding with Oct4, but not Nanog. Low expression
of Sox2 at the posterior region of E6.5 epiblast suggested that
binding of a complex containing Oct4 and Smad2 to the Nanog
promoter might be sufﬁcient for promoting Nanog expression in
the posterior region of the E6.5 epiblast.
In conclusion, Nanog is required for maintenance of pluripo-
tency in E5.5–E6.5 early implantation embryos. Nanog
transcription in E6.5 epiblast is regulated by Nodal/Smad2
signaling pathways in a VE-dependent manner. In embryonic
development, a complex binding to the Nanog promoter changes
from Esrrb/Oct4/Sox2 in ES /ICM cells to Smad2/Oct4/Sox2 in
EpiSCs/E5.5 epiblast. Subsequently, Nanog expression skews
toward posterior E6.5 epiblast and coincides with Oct4 and Nodal
expression pattern, which is opposite of Sox2 patterning, suggest-
ing a potentially reduced role of Sox2 in Nanog regulation (Fig. 6).
Discussion
Here, we demonstrate that (1) Nanog plays a crucial role
in stabilizing pluripotency of cells in the epiblast of post-
Smad2 Oct4Esrrb
TCCCA GTCT GGGTCAC CTTACAGCTTCT  TTTGCAT TACAATGTCCATGGT
-180 -131Esrrb Oct4
Smad2
Nanog
-176 -154
TSS
A CB
Epiblast
3
2.5
2
1.5
1
0.5
0
A B C
   EpiSCs
5
4
3
2
1
0
A B C
4.5
3.5
2.5
1.5
0.5
  ESCs
5
4
3
2
1
0
A B C
Fo
ld
 E
nr
ic
hm
en
t o
ve
r R
eg
io
n 
A 3.5
4*
#
6 Smad2
Oct4
Esrrb
R
el
at
iv
e 
E
xp
re
ss
io
n 
Le
ve
l
ESCs
EpiSCs
1
10
10
Esrrb Stella Klf4 Nanog Smad2Oct4
    ESCs/EpiSCs  ESCs
Sox17 Fgf5
  EpiSCs
Sox2
*
*
*
104
103
2
#
Fig. 4. Binding of Smad2 and Oct4 to Nanog promoter in E6.5 epiblast: (A) expression of pluripotency marker genes relative to Gapdh in ESCs and EpiSCs. Expression level of
Gapdh is set at 105. Esrrb is expressed in ESCs, but not EpiSCs, while Smad2 is in both ESCs and EpiSCs. Oct4, Sox2, and Nanog are expressed in both ESCs and EpiSCs. Data are
represented as mean7SEM. (B) Schematic representation of Smad2, Esrrb, and Oct4 binding sites upstream of Nanog transcription start site (TSS). The Smad2/Esrrb element
is 12-base pairs away from the Oct/Sox element. A, B, C are PCR-ampliﬁed regions in chromatin immunoprecipitation (ChIP) assay. (C) Binding of Oct4, Smad2, and Esrrb to
Nanog promoter in ESCs, EpiSCs, and E6.5 epiblasts. Quantitative PCR-ampliﬁed DNAs obtained by ChIP with anti-Oct4, Smad2, and Esrrb antibodies were normalized to
control region A. Results are expressed as mean7SD (n¼4) (*po0.05, #po0.1).
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implantation embryos from the egg-cylinder to primitive streak
stages, (2) Nanog expression is regulated by Nodal/Smad2 signal-
ing in a VE-dependent manner, (3) the transcription regulator
binding to the Smad2/Esrrb element in the Nanog promoter region
switches from Esrrb in ICM/ESCs to Smad2 in epiblast/EpiSCs, and
(4) skewed Nanog expression to the posterior region of the E6.5
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Fig. 5. Protein complex binding to Smad2 and Oct4 motifs in Nanog promoter: (A) mutation integration sites in Smad2, Esrrb, Sox2 and Oct4 binding sequences in Nanog
promoter. Crosses on the wild-type sequence (top) indicate mutation integration residues. Mutated DNA sequence is shown below. (B) Requirement of binding of Smad2,
Esrrb, Sox2 and Oct4 for up-regulating Nanog expression by luciferase assay in ESCs and EpiSCs. NIH3T3 cell was used as negative control, in which no expression of Nanog
was detected. Luciferase activities are shown relative to those of pGL3-Basic. Data are represented as means7SD (n¼4). (*po0.005 against WT, and #po0.001). (C) Protein
complex containing Smad2 in ESCs and EpiSCs by immunoprecipitation (IP) assays. Smad2 binds with Oct4, but not Nanog, in EpiSCs, while no Oct4 complex containing
Smad2 is detected in ESCs. Input nuclear extracts and IP samples were hybridized with the indicated antibodies.
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Fig. 6. Dynamic change of function and regulation of Nanog in early developing embryos. Function and expression pattern of Nanog dramatically changes between inner cell
mass (ICM) of the blastocyst stage at E3.5 and epiblast of the primitive streak stage at E6.5 (Top). Dynamic changes of Nanog activator complexes bind to the Nanog promoter
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epiblast is regulated by Smad2 and Oct4. In conclusion, expression
of Nanog, which is a key player in safeguarding pluripotency of the
epiblast, is regulated by Smad2/Oct4, which has switched from
Esrrb/Oct4 in ICM/ESCs, binding to the Smad2/Esrrb and Oct/Sox
elements in the Nanog promoter region.
Functional diversity of Nanog in the developing embryo
Nanog is a core factor for maintaining molecular pluripotency
circuitry (Boyer et al., 2005). In mouse, disruption of Nanog function
by gene targeting or knockdown induces differentiation of ICM and
ESCs (Hough et al., 2006; Mitsui et al., 2003), indicating that Nanog
plays a crucial role in maintaining pluripotency through inhibition of
cell differentiation. Moreover, constitutive Nanog expression supports
cytokine-independent self-renewal of ESCs (Chambers et al., 2003),
suggesting that maintenance of pluripotency is associated with
robust cell proliferation. Interestingly, Nanog exhibits distinctive
functions in mouse PGCs. Conditional Nanog knockdown in vivo
induces apoptotic cell death through disruption of a speciﬁc mole-
cular network in migrating PGCs (Yamaguchi et al., 2009). Therefore,
Nanog plays an important role in safeguarding against cell differ-
entiation in ICM, and apoptotic cell death in PGCs, indicating that
Nanog is a stage-speciﬁc multi-functional gene in developing
embryos. Notably, in the epiblast of embryos from the egg-cylinder
until primitive streak stage, Nanog plays a role in maintaining
pluripotency similar to Nanog in the ICM of E3.5 blastocysts. In
addition to being a pluripotency factor, Nanog is involved in axis
patterning as shown by skewed expression to the posterior region
relative to the anterior region, where speciﬁcation to ectoderm
occurs (Tam and Loebel, 2007) in the epiblast of E6.5 embryos.
Collectively, diverse functions of Nanog are required for proper
development of the ICM, epiblast, and migrating PGCs.
Nanog function in the posterior epiblast
Skewed expression of Nanog to the posterior region of the
epiblast of the E6.5 embryo is associated with other posterior-
speciﬁc genes including Oct4. The anterior region is speciﬁed for
ectoderm fate characterized by Sox2 expression (Avilion et al.,
2003), while the posterior region maintains pluripotency and
develops into mesendoderm lineage. A possible explanation for
the unique spatial orientation of pluripotency-associated gene
expression is that maintenance of pluripotency is required for
subsequent developmental events, including primitive streak for-
mation (Conlon et al., 1994) and germ cell speciﬁcation (Saitou
et al., 2012). One of the primary requirements for proper develop-
ment of primitive streak in the posterior-proximal epiblast is the
anterior–posterior axis dictated by Nodal/Nodal-antagonists
(Conlon et al., 1994; Perea-Gomez et al., 2002). Here, we report
that Nodal maintains pluripotency through Nanog expression in
the posterior epiblast, suggesting that Nodal plays a crucial role in
spatial and temporal regulation of pluripotency to specify germ-
layer formation. Furthermore, Germ cells, marked by fragilis, an
interferon-inducible transmembrane protein (Saitou et al., 2002)
are induced by bone morphogenetic protein (BMP) signaling from
the extraembryonic ectoderm at E6.5 (Lawson et al., 1999). BMP
signaling induces expression of the transcriptional regulators
Blimp1 and Prdm14 in the proximal epiblast of E6.5 embryos
(Ohinata et al., 2005; Saitou et al., 2012). Blimp1- and Prdm14-
positive cells form a cluster of alkaline phosphatase (AP)-positive
PGCs at the proximal region of allantois at E7.25 (Ginsburg et al.,
1990). Thus, it is likely that Nanog inhibits differentiation of the
posterior epiblast cells at E6.5 until PGCs emerge. It is speculated
that the extraembryonic BMP-responsible Smad signaling (Xu et
al., 2008) may be related to Nanog upregulation in the posterior
region of E6.5 epiblasts.
Requirement of Nanog in development
Nanog expression ﬂuctuates among mouse ESCs at the single-
cell level (Chambers et al., 2007; Hatano et al., 2005), suggesting
that transient downregulation of Nanog predisposes the cells
toward differentiation but does not mark commitment. Surpris-
ingly, Nanog-null ESCs can self-renew indeﬁnitely, although the
cells are prone to differentiation (Chambers et al., 2007). Nanog-
null ESCs can contribute to embryonic germ layers including PGCs,
but not mature germ cells, in fetal and adult chimeras (Chambers
et al., 2007). Consistent with this, Nanog function in anti-apoptotic
cell death in migrating and colonized PGCs into genital ridges is
indispensable (Yamaguchi et al., 2009). Importantly, Nanog func-
tion in stabilizing pluripotency could be substituted by other
factors or pathways, as shown by Nanog-null ESC self-renewal in
speciﬁc culture conditions, and their ability to contribute to
embryonic development in chimeras (Chambers et al., 2007;
Theunissen and Silva, 2011). Esrrb has been identiﬁed as a potent
pluripotency factor that can functionally replace Nanog in vitro
(Festuccia et al., 2012), suggesting that Esrrb may substitute Nanog
function of pluripotency stabilization in Nanog-null ESCs. How-
ever, no expression of Esrrb is detected in the epiblast, and hence,
it is unclear whether Nanog function can be replaced by other
factors in the epiblast. In EpiSCs, pluripotency is maintained with
gene expression proﬁle characterized by a low level of Nanog (Silva
et al., 2009). Moreover, it was reported that Nanog-null EpiSCs
could be derived from both in vitro and ex vivo schemes, suggest-
ing the existence of an as yet unidentiﬁed pathway that could
sustain primed pluripotency in the absence of Nanog (Osorno
et al., 2012). Thus, further analysis with EpiSCs could provide clues to
the identiﬁcation of a Nanog substitute in the epiblast, which could
play an important role in maintaining pluripotency of human ESCs.
Transcriptional regulation of Nanog in the epiblast
A complex array of gene regulatory proteins controls the
expression of Nanog: some acting as activators including Oct4,
Sox2 (Kuroda et al., 2005; Rodda et al., 2005), Esrrb (van den Berg
et al., 2008), Brachyury, and Stat3 (Suzuki et al., 2006), and others
as repressors including p53 (Lin et al., 2005), GCNF (Gu et al.,
2005), Grb2/Mek pathway (Hamazaki et al., 2006), and Tcf3
(Pereira et al., 2006). The concentrations of these regulators are
thought to change during development. Particular combination of
all the proteins triggers transcription of Nanog. A similar mechan-
ism was reported for the complex regulatory region of the human
beta-GLOBIN gene, which is part of a cluster of GLOBIN genes
(Stamatoyannopoulos, 2005). Strong activators of Nanog are Oct4,
Sox2, Esrrb, and Smad2, which bind to Oct/Sox elements and
Smad2/Esrrb elements, located around 150 base pairs upstream of
the transcriptional start site of Nanog. A Two-step switching
paradigm of transcription activator complex occurs during peri-
and postimplatation development. In ICM cells of preimplantation
blastocysts, a large gene regulatory complex containing Oct4/Sox2/
Esrrb activates Nanog transcription (Festuccia et al., 2012; Kuroda
et al., 2005; Rodda et al., 2005). Next, in E5.5 epiblasts brieﬂy after
implantation, the Nanog regulatory complex changes to Oct4/Sox2/
Smad2, due to downregulation of Esrrb. Then, during anterior–
posterior axis patterning around E6.5, we speculate that the
protein complex binding to the Nanog promoter further evolves
into Oct4/Smad2 based on our observations in Sox2 patterning of
E6.5 embryos and immunostaining of E5.5 epiblast under VE-free
condition (Fig. 6). However, the precise role of Sox2 in Nanog
regulation remains inconclusive and requires further analysis.
Epigenetic changes at the Nanog promoter region during develop-
ment, from blastocyst to the primitive streak stage, are largely
unknown. Furthermore, it is unclear how other regulatory factors
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binding to interspersed sequences around Nanog interact with
various forms of Oct4-centered complexes through control of
chromatin condensation or decondensation in embryonic devel-
opment, as observed for beta-GLOBIN (Mahajan et al., 2007). Nanog
can respond to an enormous number of combinatorial complexes
that could induce appropriate level of expression at the correct
time to ensure proper development.
Materials and methods
Cell culture
Mouse R1 ES cells were maintained in Dulbecco's modiﬁed
Eagle's medium (DMEM) (Wako) supplemented with 15% fetal
bovine serum (FBS) (Millipore), 10–4 M 2-mercaptoethanol, and
1000 U of recombinant LIF (Chemicon)/ml at 37 1C. Mouse EpiSCs
were maintained with mouse embryonic ﬁbroblast (MEF)-condi-
tioned medium (CM) (DMEM/F12 HAM (Sigma) supplemented
with 20% Knockout serum replacement (KSR) (Invitrogen), L-
glutamine, non-essential amino acids, 2-mercaptoethanol, and
10 ng/ml bFGF (Peprotech)). NIH 3T3 cells were cultured in DMEM
containing 10% fetal bovine serum.
in vitro culture of the epiblast
Female conditional Nanog-knockdown mice (NRi-Tg) were mated
with Cre-ER mice (Hayashi and McMahon, 2002; Yamaguchi et al.,
2009). To recover E6.5 embryos, females were sacriﬁced 6 days after
vaginal plug was observed. Embryos were dissected in DMEM with
FBS. To isolate the epiblasts, embryos were incubated with 0.25%
Trypsin and 1 mM EDTA (TE) for 1 min. Following three times
washes with phosphate buffered seline (PBS), visceral endoderm
was removed by gentle pipetting using mouth pipette with ﬁne-
drawn capillary (100 μm in inner-diameter). Extra-embryonic ecto-
derm was removed with a glass needle.
For ex-vivo culture, isolated epiblasts were cut into four to ﬁve
pieces by glass needle, and seeded onto feeder layer of inactivated
MEFs in EpiSC medium (DMEM/F12 HAM) with 15% KSR, L-
glutamine, non-essential amino acids, 2-mercaptoethanol, peni-
cillin, streptomycin, 10 ng/ml bFGF, and 20 μg/ml ActivinA (Pepro-
tech). To induce Nanog knockdown, 4-hydroxytamoxifen (Sigma)
was added at a concentration of 1 μM. The pan-caspase inhibitor
Z-VAD-FMK (Biomol) was used at a concentration of 20 μM.
For ﬂoating culture, epiblasts dissected from Nanog-GFP trans-
genic mouse (Okita et al., 2007) were cultured in MEF-conditioned
medium in low-cell binding U-bottom 96-well plates (Nunc).
Nodal (R&D systems) was added at a concentration of 50 μg/ml
for 12 h.
Quantitative reverse transcription PCR
Total RNA was extracted from epiblasts and cultured cells using
RNeasy mini Kit (Qiagen) and TRIzol (Invitrogen), respectively,
according to the manufacturer's instructions. DNase I (Roche
Diagnostics)-treated RNA was reverse-transcribed using random
primers and Superscript III Reverse Transcriptase (Invitrogen).
Ampliﬁcation was performed using Power SYBR Green PCR Master
Mix (Applied Biosystems) according to the manufacturer's instruc-
tions with gene-speciﬁc primer sets (Supplemental Table 1). All
reactions were carried out in duplicate and gene expression levels
were normalized to Gapdh. Relative expression of each gene was
quantiﬁed from threshold cycles for ampliﬁcation using the ΔΔCt
or ΔCt method.
Immunohistochemistry
For whole-mount indirect immunoﬂuorescence analysis, dis-
sected embryos and epiblasts were ﬁxed in 4% paraformaldehyde
in PBS for 15 min at room temperature, washed three times
with 0.1% Triton X-100 in PBS (PBST) and blocked with 3% Bovine
serum albumin (BSA; Sigma) in PBST overnight. Embryos
were then incubated with anti-Nanog (1:500; CosmoBio), anti-
Oct4 (1:50; Santa Cruz), and anti-Sox2 (1:500; gift from S.
Yamanaka) for 4 days, washed four times with PBST, incubated
overnight with secondary antibodies and 4,6-diamidino-2-phenyl-
indole (DAPI), washed four times with PBST and mounted in Slow
Fade Gold (Invitrogen) for observation by confocal microscopy
(Olympus).
Micro-chromatin immunoprecipitation
Micro-chromatin immunoprecipitation (μChIP) analysis was
performed as described previously with minor modiﬁcations
(Dahl and Collas, 2008). Mouse ESCs and EpiSCs were dissociated
into single-cell suspensions, and 1105 cells were cross-linked
with 1% formaldehyde for 8 min. DNA was fragmented by
sonication using seven 30-s pulses at 4 1C (Astrason). Immuno-
precipitation was performed using Protein G dynabeads (Invitro-
gen) bound with anti-Oct4 (Santa Cruz), anti-Smad2/3 (Cell
Signaling), or anti-Esrrb (R&D systems). Precipitated DNA was
puriﬁed and analyzed by quantitative PCR (qPCR) using the primer
sets listed in Supplemental Table 2.
ex vivo μChIP with epiblasts was performed as reported
previously (Dahl and Collas, 2008). Epiblasts were collected from
20 to 25 E6.5 embryos (C57BL/6). Single cells dissociated from
epiblasts with TE were mixed with 1106 MEFs followed by
cross-linking in PBS containing 1% formaldehyde, 10 mM Dimethyl
3,30-dithiopropionimidate dihydrochloride (DTBP) (Sigma), and
2.5 mM Dithiobis[succinimidyl propionate] (DSP) (Sigma) for
10 min (Brown et al., 2011). Precipitated DNA was puriﬁed and
analyzed by nested qPCR using the primer sets listed in
Supplemental Table 1. Genomic DNA was used as reference to
verify linear ampliﬁcation. Brieﬂy, DNAs were ampliﬁed for 15, 20,
or 25 cycles of PCR followed by puriﬁcation using Qiaquick PCR
Puriﬁcation Kit (Qiagen). The DNA was then diluted and subjected
to qPCR.
Reporter vectors and luciferase reporter assays
Construction of the luciferase reporter vector containing Nanog
promoter region (332 bp to þ50 bp) was previously described
(Kuroda et al., 2005). Oligonucleotide-directed mutations were
introduced into the Oct4, Smad2/3, and/or Esrrb binding elements
by PCR as previously reported (Zheng et al., 2004) using primers
containing nucleotide replacements listed in Supplemental
Table 3.
Mouse ESCs (5.0105), NIH 3T3 (2.5105), and rho-associated
protein kinase (ROCK) inhibitor-treated EpiSCs (1.0106) were
incubated in six-well tissue culture plates for 24 h. Each reporter
construct (1.25 pmol) was co-transfected with vector phRL-TK
(0.125 pmol) (Promega) as an internal control using Lipofectamine
2000 (Invitrogen). Cell extracts were prepared 48 h after
transfection, and luciferase activities were evaluated using a
dual-luciferase assay system (Promega). The luciferase activity of
each construct was referenced to that of control vector pGL3-Basic.
All conditions were performed in triplicate, and the promoter
activities were reported as mean7standard deviation.
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Nuclear extraction and co-immunoprecipitations (coIP)
The nuclear protein was extracted according to the method
previously reported (Dyer and Herzog, 1995). CoIP was carried out
as previously described (Vallier et al., 2009) with minor modiﬁca-
tions. Nuclear protein was diluted with HEMG110 buffer to a
concentration of 2.5 mg/ml. In each IP assay, 0.5 mg nuclear
protein and 8 μg antibody (anti-Smad2/3 (Cell Signaling), anti-
Oct4 (Santa Cruz), anti-Nanog (ReproCell)) were used and incu-
bated for 3 h at 4 1C. Protein G Dynabeads (50 μl) (Invitrogen) was
added followed by 1 h of incubation at 4 1C. The beads were then
washed with HEMG110 at ﬁve times, and then proteins were
eluted by Laemmli sample buffer at 70 1C for 15 min. Protein
samples were separated by 10% SDS-PAGE, and transferred onto a
PVDF membrane (Millipore). Membranes were probed with anti-
Oct4 (1:200) (Santa Cruz), anti-Smad2 (1:1000) (Cell Signaling),
and anti-Nanog (1:1000) (ReproCell) antibodies at 4 1C overnight.
The membranes were incubated with HRP-conjugated anti-rabbit
IgG (1:1000) (Abcam) for 1 h. Signals were visualized using ECL
Western Blotting Detection Kit (GE Healthcare).
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